Stock Screener App

Frei -

Installieren

Drug Manufacturers - General

147.23

2.93% -4.45

after-market

Handel nachbörslich: 144.50 -2.73 -1.85%

Gilead Sciences Inc (GILD)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt GILD? Forum Prognose Aktiensplit Dividendenhistorie

Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten

Gilead falls despite quarterly beats on disappointing 2026 EPS guidance - Seeking Alpha

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. - Barron's

Gilead Sciences, Inc. Increases Cash Dividend for the First Quarter of 2026, Payable on March 30, 2026 - marketscreener.com

Former Gilead execs' startup targets fresh funding based on fat-fighting drug's study results - The Business Journals

Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products - The Wall Street Journal

Earnings snapshot: Gilead guides FY26 earnings below consensus after strong Q4 - MSN

Gilead Sciences shares drop after narrow beat and in-line outlook - Investing.com

Will Gilead's solid fourth quarter be enough to shake off its light outlook? - MSN

Gilead Sciences (NASDAQ:GILD) Issues Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat

Gilead Sciences raises quarterly dividend by 3.8% to $0.82 per share - Investing.com

Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results - Business Wire

Gilead Sciences’s (NASDAQ:GILD) Q4 CY2025 Sales Beat Estimates - Yahoo Finance

Will Gilead's Solid Fourth Quarter Be Enough To Shake Off Its Light Outlook? - Investor's Business Daily

Gilead Sciences Q4 Adjusted Earnings Decline; Revenue Rises; Dividend Raised - marketscreener.com

Gilead (GILD) Anticipated to Experience Significant Post-Earnings Movement - GuruFocus

Gilead 2026 outlooks short of Wall Street view, shares fall - Reuters

(GILD) Gilead Sciences Expects 2026 Product Sales $29.6B-$30B - marketscreener.com

Gilead quarterly results beat Wall Street estimates - marketscreener.com

Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend - Business Wire

Gilead’s 2026 Forecast Falls Short of Wall Street’s Expectations - Bloomberg.com

Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse - The Chronicle-Journal

Gilead earnings up next: Can Yeztugo launch offset Q4 softness? By Investing.com - Investing.com Australia

Gilead Sciences: Buy This Stock For Both Dividend And Growth (NASDAQ:GILD) - Seeking Alpha

Wealthfront Advisers LLC Reduces Holdings in Gilead Sciences, Inc. $GILD - MarketBeat

Gilead Sciences Stock: Yield-Rich, AI-Ignored, And Suddenly Back On Wall Street’s Radar - AD HOC NEWS

Coca-Cola, Gilead, Robinhood and more set to report earnings Tuesday - Investing.com

Gilead Sciences (GILD) Poised for Q4 Earnings Beat Amid Strong D - GuruFocus

Gilead Q4 preview: Core portfolio, Yeztugo launch keep analysts optimistic ahead of earnings - Seeking Alpha

Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts? - TradingView

Should you buy Gilead Sciences before Feb. 10? - MSN

Should You Buy Gilead Sciences Before Feb. 10? - The Motley Fool

Exploring Gilead Sciences's Earnings Expectations - Benzinga

Candriam S.C.A. Has $179.86 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat

Gilead Sciences, Inc. $GILD Shares Sold by ProShare Advisors LLC - MarketBeat

Alps Advisors Inc. Increases Holdings in Gilead Sciences, Inc. $GILD - MarketBeat

Gilead Sciences (GILD) Reports Q4: Everything You Need To Know Ahead Of Earnings - Yahoo! Finance Canada

Early Trading Movement | Gilead Sciences-B Shares Surge Over 7%, With the 5-day MA Crossing Above the 10-day MA to Form a Golden Cross - 富途牛牛

Gilead stock at 52-week high after FDA Yescarta label change, with earnings next - TechStock²

Plato Investment Management Ltd Acquires 6,668 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Gilead Sciences (GILD) Is Up 7.4% After FDA Expands Yescarta Lymphoma Label Restrictions Removed - simplywall.st

Canada Post Corp Registered Pension Plan Has $11.64 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat

Assessing Gilead Sciences (GILD) Valuation After Its Strong Recent Share Price Performance - Yahoo Finance

Gilead Sciences (NASDAQ:GILD) CEO Daniel Patrick O'day Sells 115,640 Shares - MarketBeat

Gilead Sciences CEO O’Day sells $17.3 million in stock - Investing.com

Gilead Sciences CEO O’Day sells $17.3 million in stock By Investing.com - Investing.com India

Biopharma bites: Dosing pause for uniQure's gene therapy, EU OK for GSK's Nucala, and a label update for Gilead's CAR-T - FirstWord Pharma

Gilead’s Dietmar Berger Reflects On Pipeline After First Year As CMO - Citeline News & Insights

Gilead is advertising around the Super Bowl to get out the word about new HIV-prevention drug - The Business Journals

Is Gilead Sciences (GILD) a 'Buy' Ahead of Its Upcoming Earnings Announcement? - Nasdaq

Gilead (GILD) Gains FDA Nod for Expanded Use of Yescarta in Lymp - GuruFocus

FDA Updates Yescarta Label, Boosts Gilead's (GILD) Market Positi - GuruFocus

Gilead wins favorable FDA label update for Yescarta (GILD) - Seeking Alpha

Gilead Sciences Says Yescarta Won FDA Label Update, Removing Use Limits for Relapsed CNS Lymphoma Patients - marketscreener.com

Gilead Sciences (GILD) Valuation Check After Oncology And HIV Therapy Momentum - simplywall.st

J.W. Cole Advisors Inc. Purchases 7,397 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Envestnet Asset Management Inc. Lowers Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat

Is Gilead Sciences (GILD) Still Attractive After Strong Multi‑Year Share Price Gains - Yahoo Finance

Ahead of Gilead (GILD) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics - Yahoo Finance

Gilead Sciences, Inc. (GILD): A bull case theory - MSN

Ashton Thomas Private Wealth LLC Acquires 10,107 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Gilead Sciences, Inc. $GILD Stock Holdings Increased by Jones Financial Companies Lllp - MarketBeat

Machina Capital S.A.S. Makes New $1.65 Million Investment in Gilead Sciences, Inc. $GILD - MarketBeat

ABN AMRO Bank N.V. Acquires Shares of 46,091 Gilead Sciences, Inc. $GILD - MarketBeat

BI Asset Management Fondsmaeglerselskab A S Sells 60,982 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Gilead Sciences, Inc. $GILD Shares Purchased by AGF Management Ltd. - MarketBeat

Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts - Yahoo Finance

Gilead Sciences Stock Surged 50%, Here's Why - Trefis

This Overlooked Biotech Giant Could Surprise Investors This Quarter - Barchart.com

Here's Why Gilead Sciences Stock Surged 21% in a Month - Finviz

Earnings Preview: Gilead Sciences (GILD) Q4 Earnings Expected to Decline - Yahoo Finance

AMGN

$364.65

2.97%

PFE

$27.61

2.07%

NVO

$49.12

0.51%

MRK

$117.15

0.42%

AZN

$193.40

2.87%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters